C-peptide vs hGHRH(1-37)OH
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and hGHRH(1-37)OH (Human growth hormone-releasing factor (1-37) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | hGHRH(1-37)OH |
|---|---|---|
| Category | Pain Management | Growth Hormone |
| Full Name | Connecting peptide (C-peptide) | Human growth hormone-releasing factor (1-37) hydroxyl |
| Molecular Weight | 3020.3 Da | N/A |
| Half-Life | ~20-30 min | 5-20 minutes |
| Amino Acids | 31 | 37 |
| Typical Dose | no approved analgesic dose|research-only | 1-2 mcg/kg |
| Route | IV|subQ | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 60 |
| Research Status | Pre-clinical | Clinical Research |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
hGHRH(1-37)OH Benefits
- ✓GH release studies
- ✓minimal-sequence mapping
- ✓receptor pharmacology
- ✓peptide stability research
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
hGHRH(1-37)OH Dosing
1-2 mcg/kg SC or IV bolus|acute stimulation with serial GH assays|short-course research administration with biomarker monitoring
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
hGHRH(1-37)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient fatigue
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
hGHRH(1-37)OH
Human GHRF(1-37)OH has appeared in studies examining how loss of C-terminal residues affects biological activity at the GHRH receptor. It is often used alongside other fragments to define structure-activity relationships within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.